2. Academic Validation
  3. Immune-activated microspheres for enhanced chemoembolization of hepatocellular carcinoma by blocking the adenosine A2A receptor

Immune-activated microspheres for enhanced chemoembolization of hepatocellular carcinoma by blocking the adenosine A2A receptor

  • Acta Biomater. 2025 Jun 1:199:443-455. doi: 10.1016/j.actbio.2025.04.042.
Minjiang Chen 1,  Yaning Chen 2,  Weiqian Chen 3,  Xiaoxiao Chen 3,  Xiaoju Guo 3,  Junchao Yu 3,  Xinyu Guo 3,  Mengyuan Wang 4,  Xinyu Zhang 4,  Qin Hu 4,  Shiji Fang 3,  Liyun Zheng 3,  Zhongwei Zhao 3,  Yongzhong Du 5,  Gaofeng Shu 6,  Jiansong Ji 7
Affiliations

Affiliations

  • 1 Zhejiang Key Laboratory of Imaging and Interventional Medicine, School of Medicine, Lishui Hospital of Zhejiang University, Zhejiang, China; Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University, Zhejiang, China; Cixi Biomedical Research Institute, Wenzhou Medical University, Zhejiang, China.
  • 2 Zhejiang Key Laboratory of Imaging and Interventional Medicine, School of Medicine, Lishui Hospital of Zhejiang University, Zhejiang, China.
  • 3 Zhejiang Key Laboratory of Imaging and Interventional Medicine, School of Medicine, Lishui Hospital of Zhejiang University, Zhejiang, China; Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
  • 4 Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University, Zhejiang, China; Cixi Biomedical Research Institute, Wenzhou Medical University, Zhejiang, China.
  • 5 Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, China. Electronic address: duyongzhong@zju.edu.cn.
  • 6 Zhejiang Key Laboratory of Imaging and Interventional Medicine, School of Medicine, Lishui Hospital of Zhejiang University, Zhejiang, China; Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University, Zhejiang, China; Cixi Biomedical Research Institute, Wenzhou Medical University, Zhejiang, China. Electronic address: shugf1208@gmail.com.
  • 7 Zhejiang Key Laboratory of Imaging and Interventional Medicine, School of Medicine, Lishui Hospital of Zhejiang University, Zhejiang, China; Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University, Zhejiang, China; School of Medicine, Lishui University, Zhejiang, China. Electronic address: jjstcty@wmu.edu.cn.
PMID: 40274057 DOI: 10.1016/j.actbio.2025.04.042
Abstract

Transcatheter arterial chemoembolization (TACE) stands as the frontline strategy for unresectable hepatocellular carcinoma (HCC), effectively eliminating Cancer cells through direct cytotoxicity and immunogenic cell death (ICD). However, TACE triggers rapid tumor Apoptosis, which promotes the release of intracellular ATP into the extracellular space. This ATP is sequentially hydrolyzed to adenosine (ADO) by ectonucleotidases (CD39 and CD73) overexpressed in the tumor microenvironment (TME), resulting in ADO accumulation. The ensuing ADO pathway-mediated immunosuppression via adenosine 2A receptors (A2AR) signaling severely limits TACE-induced ICD efficacy, resulting in poor prognosis. To address this, we developed gelatin microspheres co-loaded with doxorubicin (DOX) and the A2AR antagonist SCH-58,261, in which SCH-58,261 was loaded into solid lipid nanoparticle (SLNP) due to its poor water solubility. The microspheres (SLNP-SCH/DOX@MS) showed an average size of 49 ± 13 μm, with the capable of complete tumor vascular embolization, and sustained release profiles of both DOX and SCH-58,261 over 30 days. In vitro and in vivo studies indicated that SLNP-SCH/DOX@MS not only enhanced tumor cell Apoptosis but also amplified ICD-mediated dendritic cell maturation and antigen presentation. Moreover, SCH-58,261 counteracted TACE-triggered ADO accumulation by competitively binding to A2AR on immune cells, thereby reversing dendritic cell dysfunction and CD8+T cell exhaustion. This dual-action strategy synergized ICD-driven immunostimulation with ADO pathway blockade, reshaping the TME. Our findings highlight the potential of SLNP-SCH/DOX@MS to address the delicate equilibrium between ICD-induced immunity and ADO-mediated immunosuppression for improved HCC treatment. STATEMENT OF SIGNIFICANCE: This study introduces a approach to improve transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) by addressing the adenosine (ADO) pathway, a known barrier to effective immunogenic cell death (ICD). We developed gelatin microspheres co-loaded with doxorubicin (DOX) and the A2AR antagonist SCH-58,261, which significantly enhance TACE-induced immunity by promoting ICD and counteracting ADO-mediated immunosuppression. In vitro and in vivo results demonstrate robust dendritic cell maturation and amplified tumor-specific immune responses, indicating improved antitumor efficacy. This work provides a promising strategy to optimize TACE for HCC treatment, offering our readership a therapeutic solution that bridges Cancer treatment and immunomodulation.

Keywords

Drug-loaded microspheres; Hepatocellular carcinoma; Immunogenic cell death; Immunotherapy; Transcatheter arterial chemoembolization.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z